Accepted Manuscript

Pathologic Upgrade Rates of High-Risk Breast Lesions on Digital 2-Dimensional vs Tomosynthesis Mammography

Leslie R. Lamb, MD, MSc, Manisha Bahl, MD, MPH, Kevin S. Hughes, MD, FACS, Constance D. Lehman, MD, PhD

PII: S1072-7515(18)30032-2

DOI: 10.1016/j.jamcollsurg.2017.12.049

Reference: ACS 9006

To appear in: Journal of the American College of Surgeons

Received Date: 21 September 2017

Revised Date: 29 December 2017

Accepted Date: 29 December 2017

Please cite this article as: Lamb LR, Bahl M, Hughes KS, Lehman CD, Pathologic Upgrade Rates of High-Risk Breast Lesions on Digital 2-Dimensional vs Tomosynthesis Mammography, *Journal of the American College of Surgeons* (2018), doi: 10.1016/j.jamcollsurg.2017.12.049.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Pathologic Upgrade Rates of High-Risk Breast Lesions on Digital 2-Dimensional vs Tomosynthesis Mammography

Leslie R Lamb¹, MD, MSc, Manisha Bahl¹, MD, MPH, Kevin S Hughes², MD, FACS, Constance D Lehman¹, MD, PhD

¹Department of Radiology, Massachusetts General Hospital, Boston, MA ²Department of Surgery, Massachusetts General Hospital, Boston, MA

Disclosure Information: Nothing to disclose.

Disclosures outside the scope of this work: Dr Hughes receives honoraria from Myriad Genetics, Veritas Genetics, and Focal Therapeutics (surgical implant for radiation planning with breast conservation) and is a founder of and has financial interest in CRA Health (formerly Hughes RiskApps). Dr Lehman has a research grant from GE Healthcare and is on the Advisory Board for GE Healthcare.

Disclaimer: Dr. Hughes' interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.

Correspondence address: Manisha Bahl, MD, MPH 55 Fruit Street, WAC 240 Boston, MA 02114 Telephone: 617-726-3093 Fax: 617-726-1074 E-mail: mbahl1@mgh.harvard.edu Download English Version:

https://daneshyari.com/en/article/8833566

Download Persian Version:

https://daneshyari.com/article/8833566

Daneshyari.com